---
title: "Retinal Diseases"
order: 4
category: "Ophthalmology"
---

# Retinal Diseases

## Overview

The retina is the light-sensitive neural tissue lining the inner eye that converts light into electrical signals for transmission to the brain via the optic nerve. Retinal diseases encompass a wide spectrum of conditions affecting the retina, choroid, and vitreous, ranging from vascular disorders to degenerative diseases. Major categories include diabetic retinopathy, age-related macular degeneration, retinal vascular occlusions, and retinal detachment. These conditions are leading causes of vision loss worldwide. Understanding retinal anatomy, pathophysiology, clinical presentations, imaging modalities, and treatment options is essential for preserving vision.

### Epidemiology
- **Diabetic retinopathy**: Leading cause of blindness in working-age adults
- **Age-related macular degeneration**: Leading cause of vision loss in elderly (>50 years)
- **Retinal vein occlusion**: Second most common retinal vascular disease after diabetic retinopathy
- **Retinal detachment**: Affects 1 in 10,000 annually
- **Impact**: Significant burden on quality of life and healthcare systems
- **Preventable vision loss**: Many conditions treatable if detected early

### Classification
- **Vascular diseases**: Diabetic retinopathy, vein/artery occlusions, hypertensive retinopathy
- **Degenerative diseases**: Age-related macular degeneration, inherited retinal dystrophies
- **Structural diseases**: Retinal detachment, macular hole, epiretinal membrane
- **Inflammatory diseases**: Uveitis, retinitis
- **Neoplastic diseases**: Retinoblastoma, choroidal melanoma

## Retinal Anatomy and Physiology

### Retinal Layers (Inner to Outer)

1. **Internal limiting membrane**: Basement membrane of Müller cells
2. **Nerve fiber layer**: Retinal ganglion cell axons
3. **Ganglion cell layer**: Ganglion cell bodies
4. **Inner plexiform layer**: Synapses between bipolar and ganglion cells
5. **Inner nuclear layer**: Bipolar, horizontal, amacrine cell bodies
6. **Outer plexiform layer**: Synapses between photoreceptors and bipolar cells
7. **Outer nuclear layer**: Photoreceptor nuclei
8. **External limiting membrane**: Müller cell junctions
9. **Photoreceptor inner/outer segments**: Rods and cones
10. **Retinal pigment epithelium (RPE)**: Single layer of hexagonal cells

### Macula and Fovea

#### Macula
- **Location**: Central 5-6 mm of retina
- **Function**: High-resolution central vision
- **Layers**: All retinal layers present except at foveal center
- **Vascular supply**: Dual (retinal and choroidal)

#### Fovea
- **Central depression**: 1.5 mm diameter
- **Foveola**: Central 0.35 mm, only cones present
- **Cone density**: Maximum cone density (150,000-200,000/mm²)
- **No inner retinal layers**: Displaced laterally for optical clarity
- **Highest visual acuity**: 20/20 to 20/10

### Blood Supply

#### Retinal Circulation
- **Central retinal artery**: Branch of ophthalmic artery
- **Four main branches**: Superior and inferior temporal and nasal arteries
- **Supply**: Inner retina (inner 2/3)
- **End-arterial**: No anastomoses (occlusion causes infarction)

#### Choroidal Circulation
- **Posterior ciliary arteries**: From ophthalmic artery
- **Supply**: Outer retina (outer 1/3), RPE, photoreceptors
- **High flow**: Highest blood flow per tissue weight in body
- **Choriocapillaris**: Fenestrated capillaries adjacent to RPE

### Photoreceptors

#### Rods
- **Number**: ~120 million per eye
- **Distribution**: Throughout retina, peak at 20° from fovea
- **Function**: Scotopic (low light) vision, motion detection
- **Sensitivity**: High sensitivity, low resolution
- **Photopigment**: Rhodopsin

#### Cones
- **Number**: ~6 million per eye
- **Distribution**: Concentrated in fovea
- **Function**: Photopic (bright light) vision, color vision, high acuity
- **Types**: S-cones (blue), M-cones (green), L-cones (red)
- **Photopigments**: Photopsins

## Diabetic Retinopathy

### Pathophysiology

#### Hyperglycemia Effects
- **Polyol pathway**: Sorbitol accumulation in retinal cells
- **Advanced glycation end products (AGEs)**: Protein cross-linking
- **Protein kinase C activation**: Altered vascular permeability
- **Oxidative stress**: Increased free radicals
- **Inflammation**: Leukostasis, cytokine release

#### Vascular Changes
- **Pericyte loss**: Early event, capillary instability
- **Basement membrane thickening**: Vascular dysfunction
- **Endothelial cell damage**: Increased permeability
- **Capillary occlusion**: Retinal ischemia
- **Microaneurysms**: Outpouching of capillary walls

#### Vascular Permeability
- **VEGF upregulation**: From retinal ischemia
- **Breakdown of blood-retinal barrier**: Leakage
- **Macular edema**: Fluid accumulation in macula
- **Hard exudates**: Lipid deposition

#### Neovascularization
- **Ischemia**: Triggers VEGF and other growth factors
- **New vessels**: Fragile, prone to hemorrhage
- **Locations**: Optic disc (NVD), elsewhere (NVE)
- **Complications**: Vitreous hemorrhage, tractional retinal detachment

### Classification

#### Non-Proliferative Diabetic Retinopathy (NPDR)

**Mild NPDR:**
- Microaneurysms only
- Few retinal hemorrhages

**Moderate NPDR:**
- More than just microaneurysms
- Less than severe NPDR
- Hemorrhages and/or microaneurysms
- Soft exudates (cotton-wool spots)
- Venous beading in <1 quadrant
- IRMA (intraretinal microvascular abnormalities) in <1 quadrant

**Severe NPDR (4-2-1 rule):**
Any of:
- Hemorrhages/microaneurysms in 4 quadrants
- Venous beading in 2 or more quadrants
- IRMA in 1 or more quadrants

#### Proliferative Diabetic Retinopathy (PDR)
- **Neovascularization**: NVD or NVE
- **Vitreous/preretinal hemorrhage**: From new vessels
- **Fibrovascular proliferation**: Scar tissue
- **Tractional retinal detachment**: From contracting fibrosis

#### Diabetic Macular Edema (DME)
- **CI-DME**: Clinically significant macular edema
  - Thickening within 500 μm of fovea
  - Hard exudates within 500 μm with adjacent thickening
  - Thickening >1 disc area within 1 disc diameter of fovea
- **Center-involved DME**: Foveal center involved on OCT

### Risk Factors
- **Duration of diabetes**: Most important factor
- **Glycemic control**: HbA1c level correlates with risk and progression
- **Hypertension**: Independent risk factor
- **Hyperlipidemia**: Associated with retinopathy and exudates
- **Pregnancy**: Can accelerate retinopathy
- **Nephropathy**: Marker of microvascular disease
- **Type of diabetes**: Both type 1 and type 2 at risk

### Clinical Presentation

#### Symptoms
- **Early**: Often asymptomatic
- **Macular edema**: Blurred central vision, metamorphopsia
- **Vitreous hemorrhage**: Sudden vision loss, floaters
- **Tractional RD**: Progressive visual field loss

#### Examination Findings
- **Microaneurysms**: Red dots, earliest sign
- **Hemorrhages**: Dot-blot (deep) or flame (superficial)
- **Hard exudates**: Yellow lipid deposits
- **Cotton-wool spots**: Nerve fiber layer infarcts (soft exudates)
- **IRMA**: Shunt vessels within retina
- **Venous changes**: Beading, loops, dilation
- **Neovascularization**: Fine vessels on disc or retina
- **Vitreous hemorrhage**: Red blood cells in vitreous cavity
- **Tractional RD**: Elevated retina pulled by fibrovascular membranes

### Diagnosis and Monitoring

#### Clinical Examination
- **Visual acuity**: Baseline and monitoring
- **Dilated fundus exam**: Detailed retinal evaluation
- **Slit-lamp biomicroscopy**: Macular assessment with 78D or 90D lens
- **Indirect ophthalmoscopy**: Peripheral retina

#### Imaging

**Fundus photography:**
- **7-field stereoscopic**: ETDRS standard
- **Wide-field**: Ultra-widefield imaging
- **Documentation**: Baseline and progression

**Optical coherence tomography (OCT):**
- **Macular thickness**: Quantitative measurement
- **Intraretinal fluid**: Cystoid spaces
- **Subretinal fluid**: Fluid under neurosensory retina
- **Epiretinal membrane**: Associated findings
- **OCT-angiography (OCTA)**: Non-invasive capillary imaging

**Fluorescein angiography (FA):**
- **Microaneurysms**: Hyperfluorescent dots
- **Capillary non-perfusion**: Areas of ischemia
- **Leakage**: From vessels, microaneurysms
- **Neovascularization**: Leaking new vessels
- **Macular ischemia**: Foveal avascular zone enlargement

### Treatment

#### Glycemic Control
- **DCCT/UKPDS**: Intensive control reduces incidence and progression
- **Target**: HbA1c <7% (individualized)
- **Importance**: Cornerstone of management

#### Blood Pressure Control
- **UKPDS**: BP control reduces progression
- **Target**: <130/80 mmHg for most diabetics

#### Lipid Management
- **Fenofibrate**: May reduce progression (FIELD, ACCORD Eye studies)
- **Statins**: General cardiovascular benefit

#### Screening Guidelines
- **Type 1 diabetes**: Within 5 years of diagnosis, then annual
- **Type 2 diabetes**: At diagnosis, then annual
- **Pregnancy**: Before conception and each trimester
- **More frequent**: If retinopathy present

#### Laser Photocoagulation

**Focal/grid laser for DME:**
- **Focal**: Treat leaking microaneurysms
- **Grid**: Treat diffuse edema
- **Less commonly used**: Since anti-VEGF era
- **ETDRS study**: Established benefit

**Panretinal photocoagulation (PRP) for PDR:**
- **Mechanism**: Ablate ischemic retina, reduce VEGF
- **Pattern**: 1200-2000 burns in periphery, sparing macula
- **Timing**: High-risk PDR or earlier with severe NPDR in poor follow-up
- **DRS study**: Established benefit, reduces severe vision loss
- **Side effects**: Peripheral vision loss, night vision reduction, rarely choroidal effusion

#### Anti-VEGF Therapy

**Indications:**
- **DME**: First-line for center-involved DME
- **PDR**: Alternative to or in addition to PRP

**Agents:**
- Bevacizumab (Avastin) - off-label
- Ranibizumab (Lucentis)
- Aflibercept (Eylea)
- Brolucizumab (Beovu)
- Faricimab (Vabysmo)

**Mechanism:**
- Inhibit VEGF, reduce permeability and neovascularization

**Dosing:**
- **Loading**: Often monthly × 3-6 months
- **Maintenance**: Monthly, treat-and-extend, or PRN
- **Longer-acting**: Faricimab up to q16 weeks

**Efficacy:**
- **DME**: DRCR.net Protocol I, T - superior to laser
- **PDR**: DRCR.net Protocol S - non-inferior to PRP with better vision outcomes

**Side effects:**
- **Ocular**: Endophthalmitis (rare, 0.05%), retinal detachment, cataract progression
- **Systemic**: Theoretical cardiovascular risk (controversial)

#### Corticosteroids

**Intravitreal steroids for DME:**
- **Triamcinolone**: Off-label, effective but temporary
- **Dexamethasone implant (Ozurdex)**: Sustained release, 3-6 month duration
- **Fluocinolone implant (Iluvien)**: Longer duration (3 years)

**Indications:**
- Refractory to anti-VEGF
- Pseudophakic (no cataract risk)

**Side effects:**
- Cataract (phakic patients)
- IOP elevation (30-40%)
- Endophthalmitis risk

#### Vitrectomy

**Indications:**
- Vitreous hemorrhage (not clearing)
- Tractional retinal detachment (involving or threatening macula)
- Combined tractional-rhegmatogenous RD
- Dense premacular hemorrhage

**Procedure:**
- Remove vitreous and blood
- Peel fibrovascular membranes
- Endolaser photocoagulation
- Address retinal breaks if present

## Age-Related Macular Degeneration (AMD)

### Pathophysiology

#### Aging Changes
- **Bruch membrane thickening**: Lipid deposition
- **RPE dysfunction**: Reduced phagocytosis of photoreceptor outer segments
- **Drusen formation**: Extracellular deposits between RPE and Bruch membrane
- **Oxidative stress**: Accumulation of oxidative damage

#### Dry (Non-Exudative) AMD
- **RPE atrophy**: Loss of RPE cells
- **Photoreceptor loss**: Secondary to RPE dysfunction
- **Geographic atrophy**: Advanced stage with well-demarcated areas of RPE loss

#### Wet (Exudative/Neovascular) AMD
- **Choroidal neovascularization (CNV)**: New vessels from choroid breach Bruch membrane
- **Type 1 (occult)**: Vessels beneath RPE
- **Type 2 (classic)**: Vessels above RPE, beneath neurosensory retina
- **Type 3**: Retinal angiomatous proliferation (RAP), vessels from retina
- **VEGF-driven**: Hypoxia and inflammation drive VEGF production
- **Exudation**: Fluid, blood, lipid leakage from CNV

### Risk Factors

#### Non-Modifiable
- **Age**: Most important risk factor, increases exponentially after 50
- **Genetics**: CFH, ARMS2/HTRA1, C2, C3, CFB genes
- **Family history**: 3-6× increased risk with affected first-degree relative
- **Race**: Higher in Caucasians
- **Eye color**: Light iris color

#### Modifiable
- **Smoking**: 2-3× increased risk, dose-dependent
- **Cardiovascular disease**: Hypertension, atherosclerosis
- **Obesity**: Increased risk especially of progression
- **Diet**: Low antioxidants, high fat diet
- **Sun exposure**: UV light (controversial)

### Classification

#### Early AMD
- **Medium drusen**: 63-125 μm
- **Pigmentary changes**: Hyper- or hypopigmentation
- **No visual symptoms**: 20/20 vision typically

#### Intermediate AMD
- **Large drusen**: >125 μm
- **Geographic atrophy**: Not involving fovea
- **Mild vision changes**: 20/40 or better typically

#### Advanced AMD

**Geographic atrophy (dry AMD):**
- Well-demarcated atrophy of RPE and photoreceptors
- Central involvement: Affects vision
- Progressive: Slow expansion (median 1.8 mm²/year)

**Neovascular AMD (wet AMD):**
- Choroidal neovascularization
- Rapid vision loss if untreated
- Treatable with anti-VEGF

### Clinical Presentation

#### Symptoms
- **Early**: Asymptomatic or minimal
- **Intermediate**: Difficulty with reading, dim light
- **Geographic atrophy**: Progressive central scotoma
- **Neovascular AMD**: Sudden decrease in vision, metamorphopsia, central scotoma

#### Examination Findings

**Dry AMD:**
- Drusen (small, medium, large)
- Pigmentary changes
- Geographic atrophy (sharply demarcated)
- Preserved retinal architecture

**Wet AMD:**
- Subretinal/intraretinal fluid
- Hemorrhage (subretinal, sub-RPE)
- Lipid exudates
- Pigment epithelial detachment (PED)
- Disciform scar (end-stage)

### Diagnosis and Monitoring

#### Clinical Examination
- **Visual acuity**: ETDRS chart
- **Amsler grid**: Self-monitoring for metamorphopsia
- **Dilated fundus exam**: Drusen, pigment, hemorrhage, fluid
- **Fundus photography**: Documentation

#### Optical Coherence Tomography (OCT)
- **Retinal thickness**: Quantitative measurements
- **Intraretinal fluid**: Cystoid spaces
- **Subretinal fluid**: Below neurosensory retina
- **Sub-RPE fluid**: PED
- **RPE elevation**: PED characterization
- **Hyperreflective foci**: Intraretinal inflammatory cells

#### Fluorescein Angiography (FA)
- **CNV patterns**: Classic (well-demarcated hyperfluorescence), occult (irregular)
- **Leakage**: From CNV
- **Staining**: Drusen, RPE defects
- **Less commonly used**: Since OCT era, but helpful in some cases

#### OCT-Angiography (OCTA)
- **Non-invasive**: No dye injection
- **CNV detection**: Visualize neovascular network
- **Type 1 vs Type 2**: Characterize CNV
- **Limitations**: No leakage information

#### Fundus Autofluorescence (FAF)
- **RPE health**: Lipofuscin autofluorescence
- **Geographic atrophy**: Hypoautofluorescence
- **Junctional zone**: Hyperautofluorescence at border (predictor of growth)

### Treatment

#### Dry AMD

**Lifestyle modifications:**
- **Smoking cessation**: Critical
- **Diet**: Mediterranean diet, fish (omega-3), green leafy vegetables
- **Exercise**: Regular physical activity
- **UV protection**: Sunglasses

**AREDS2 supplementation (intermediate/advanced AMD in one eye):**
- **Formulation**:
  - Vitamin C: 500 mg
  - Vitamin E: 400 IU
  - Lutein: 10 mg
  - Zeaxanthin: 2 mg
  - Zinc oxide: 80 mg
  - Cupric oxide: 2 mg
- **Efficacy**: 25% reduction in progression to advanced AMD
- **Not for prevention**: No benefit in early AMD or healthy eyes

**Emerging therapies for geographic atrophy:**
- **Complement inhibitors**: Pegcetacoplan (Syfovre), avacincaptad pegol (Izervay)
- **Mechanism**: Inhibit complement cascade
- **Efficacy**: Slow growth rate by ~20-30%
- **Approval**: FDA approved 2023

**Low vision aids:**
- Magnifiers, telescopic glasses, electronic devices
- Rehabilitation services

#### Wet (Neovascular) AMD

**Anti-VEGF therapy (first-line):**

**Agents:**
- Ranibizumab (Lucentis)
- Aflibercept (Eylea)
- Brolucizumab (Beovu)
- Bevacizumab (Avastin) - off-label
- Faricimab (Vabysmo) - dual VEGF/Ang-2 inhibitor

**Regimens:**
- **Fixed monthly**: Most intensive, best vision outcomes
- **Treat-and-extend (TAE)**: Start monthly, extend if dry, contract if fluid recurs
- **PRN (as needed)**: Treat only when active disease
- **Studies**: CATT, VIEW, HARBOR established efficacy

**Typical protocol:**
- Loading: 3 monthly injections
- Maintenance: Monthly, TAE, or PRN based on protocol
- Monitoring: OCT at each visit

**Outcomes:**
- MARINA/ANCHOR: ~30% gain ≥3 lines, 90% maintain vision
- Most maintain or improve vision with treatment
- Need for chronic, long-term therapy

**Photodynamic therapy (PDT):**
- **Mechanism**: Verteporfin activated by laser, destroys CNV
- **Rarely used**: Largely replaced by anti-VEGF
- **Possible role**: Polypoidal choroidal vasculopathy, recalcitrant PEDs

**Laser photocoagulation:**
- **Historical**: Extrafoveal CNV (now rare)
- **Destructive**: Causes scotoma
- **Replaced by**: Anti-VEGF therapy

#### Combination Therapy
- **Anti-VEGF + PDT**: Some studies suggest benefit for Type 1 CNV
- **Anti-VEGF + steroids**: Under investigation

## Retinal Vascular Occlusions

### Retinal Vein Occlusion

#### Central Retinal Vein Occlusion (CRVO)

**Pathophysiology:**
- Thrombus at lamina cribrosa
- Outflow obstruction
- Venous stasis, increased pressure
- Hemorrhages, edema, ischemia

**Risk factors:**
- Age, hypertension, glaucoma, hypercoagulable states, atherosclerosis

**Classification:**
- **Ischemic CRVO**: >10 disc areas of non-perfusion on FA
- **Non-ischemic CRVO**: <10 disc areas
- **Conversion**: 15% of non-ischemic convert to ischemic

**Clinical presentation:**
- Sudden painless vision loss
- Diffuse retinal hemorrhages ("blood and thunder")
- Dilated tortuous veins
- Cotton-wool spots
- Optic disc edema

**Complications:**
- Macular edema
- Neovascularization (iris, angle, disc, retina)
- Neovascular glaucoma

**Treatment:**
- Anti-VEGF for macular edema
- Panretinal photocoagulation for neovascularization
- Monitor for neovascular glaucoma

#### Branch Retinal Vein Occlusion (BRVO)

**Pathophysiology:**
- Thrombus at arteriovenous crossing
- Arterial compression of vein
- Sectoral venous obstruction

**Clinical presentation:**
- Sudden vision loss (if macula involved)
- Flame hemorrhages in affected quadrant/sector
- Cotton-wool spots
- Venous dilation distal to occlusion

**Treatment:**
- Anti-VEGF for macular edema
- Focal laser for persistent edema (less common now)
- Sectoral PRP for neovascularization

### Retinal Artery Occlusion

#### Central Retinal Artery Occlusion (CRAO)

**Pathophysiology:**
- Embolic (most common): From carotid, heart
- Thrombotic: Atherosclerosis
- Arteritic: Giant cell arteritis (GCA)
- Inner retinal ischemia and infarction

**Clinical presentation:**
- **Sudden profound vision loss**: Painless, seconds to minutes
- **Cherry-red spot**: Fovea (choriocapillaris shows through thin fovea)
- **Pale retina**: Retinal whitening from edema
- **Attenuated vessels**: Narrowed arterioles
- **Boxcarring**: Segmentation of blood column in vessels
- **RAPD**: Marcus Gunn pupil

**Emergency management:**
- **Ocular massage**: Attempt to dislodge embolus
- **Anterior chamber paracentesis**: Lower IOP abruptly
- **Hyperbaric oxygen**: If available within 24 hours (controversial)
- **Systemic evaluation**: Rule out GCA (ESR, CRP), carotid disease, cardiac source

**Prognosis:**
- **Poor**: Most patients have permanent severe vision loss
- **Time-sensitive**: Retina tolerates ischemia for ~90 minutes
- **Recovery**: Rare, usually if cilioretinal artery spares fovea

#### Branch Retinal Artery Occlusion (BRAO)

**Clinical presentation:**
- Sudden sectoral visual field defect
- Corresponding retinal whitening
- Better prognosis than CRAO

**Management:**
- Similar evaluation for embolic source
- Rule out GCA
- Cardiovascular risk factor management

#### Giant Cell Arteritis (GCA)
- **Consider in all**: CRAO/AION in patients >50 years
- **Symptoms**: Headache, jaw claudication, scalp tenderness, fever, malaise, PMR
- **Testing**: ESR, CRP (both often >50)
- **Temporal artery biopsy**: Gold standard, but treat empirically first
- **Treatment**: High-dose steroids immediately (prednisone 1 mg/kg)
- **Vision at risk**: Fellow eye at high risk without treatment

## Retinal Detachment

### Rhegmatogenous Retinal Detachment (RRD)

#### Pathophysiology
- **Retinal break**: Full-thickness hole or tear
- **Vitreous traction**: Posterior vitreous detachment (PVD) causes tear
- **Fluid**: Liquefied vitreous enters subretinal space through break
- **Detachment**: Neurosensory retina separates from RPE

#### Risk Factors
- **Myopia**: 5-10× increased risk with high myopia
- **PVD**: Acute PVD high risk period
- **Lattice degeneration**: Peripheral retinal thinning
- **Trauma**: Blunt or penetrating
- **Previous RD**: Fellow eye 10-15% risk
- **Cataract surgery**: 0.5-2% risk
- **Family history**: Genetic predisposition

#### Clinical Presentation

**Symptoms:**
- **Flashes (photopsia)**: Vitreous traction on retina
- **Floaters**: From PVD, Shafer sign (pigment cells)
- **Visual field defect**: Curtain or shadow
- **Decreased vision**: If macula involved

**Signs:**
- **Elevated retina**: Undulating, mobile
- **Retinal tears**: Horseshoe, operculated, giant tear
- **Shafer sign**: Pigment cells in anterior vitreous (tobacco dust)
- **Reduced IOP**: Compared to fellow eye

#### Diagnosis
- **Dilated exam**: Indirect ophthalmoscopy essential
- **Scleral depression**: Examine far periphery
- **B-scan ultrasound**: If view obscured by hemorrhage/cataract

#### Treatment

**Pneumatic retinopexy:**
- **Indications**: Single superior break, <1 clock hour
- **Procedure**: Intravitreal gas bubble, position patient
- **Laser/cryo**: Around break
- **Success rate**: 70-80%
- **Advantages**: Office-based, minimally invasive

**Scleral buckle:**
- **Mechanism**: Indent sclera, relieve vitreous traction, close break
- **Procedure**: Silicone band or sponge sutured to sclera, cryo to break
- **Success rate**: 80-90%
- **Advantages**: No intraocular manipulation, permanent
- **Complications**: Refractive change, diplopia, infection

**Pars plana vitrectomy (PPV):**
- **Mechanism**: Remove vitreous, drain fluid, gas or oil tamponade
- **Procedure**: 23, 25, or 27-gauge vitrectomy, laser around breaks
- **Tamponade**: Gas (SF6, C3F8) or silicone oil
- **Success rate**: 85-95%
- **Advantages**: Handles complex detachments, PVR
- **Complications**: Cataract, IOP changes, infection

**Combined scleral buckle + vitrectomy:**
- Complex RRDs, multiple breaks, inferior breaks, PVR

#### Positioning
- **Gas tamponade**: Face-down or specific positioning for 1-2 weeks
- **Critical**: For reattachment
- **Duration**: Depends on gas type (SF6: 2 weeks, C3F8: 6-8 weeks)

#### Prognosis
- **Anatomic success**: 85-95% single surgery
- **Visual outcomes**: Depends on macula involvement and duration
- **Macula-on RD**: 75% regain 20/40 or better
- **Macula-off RD**: 40-50% regain 20/40 or better
- **Metamorphopsia**: Common even with successful reattachment

### Tractional Retinal Detachment
- **Mechanism**: Membranes pull retina from RPE
- **No retinal break**: Intact retina
- **Causes**: Proliferative diabetic retinopathy, penetrating trauma, ROP
- **Treatment**: Vitrectomy to relieve traction

### Exudative (Serous) Retinal Detachment
- **Mechanism**: Fluid accumulation from choroidal/retinal vessels
- **No retinal break**: Intact retina
- **Causes**: Inflammatory (Vogt-Koyanagi-Harada, sympathetic ophthalmia), neoplastic (choroidal melanoma), central serous chorioretinopathy
- **Treatment**: Address underlying cause

## Macular Hole

### Pathophysiology
- **Tangential traction**: Vitreous traction on fovea
- **Foveal detachment**: Partial-thickness initially
- **Full-thickness defect**: Complete macular hole
- **Operculum**: Lid of tissue may be seen if complete PVD

### Stages (Gass Classification)
- **Stage 1**: Foveal detachment (yellow spot), impending hole
- **Stage 2**: Small full-thickness hole (<400 μm)
- **Stage 3**: Full-thickness hole (>400 μm) without PVD
- **Stage 4**: Full-thickness hole with complete PVD

### Clinical Presentation
- **Symptoms**: Decreased central vision, metamorphopsia, central scotoma
- **Watzke-Allen sign**: Break in slit beam when crossing hole

### Diagnosis
- **OCT**: Definitive, shows full-thickness defect, measures size

### Treatment
- **Observation**: Stage 1, may resolve spontaneously
- **Vitrectomy + gas + ILM peel + positioning**: Stages 2-4
  - Success rate: 85-95% closure
  - Face-down positioning: 1-2 weeks
  - Visual improvement: Depends on duration and size

### Prognosis
- **Smaller, shorter duration**: Better outcomes
- **Visual acuity**: 50-75% achieve 20/40 or better
- **Chronic holes**: Lower success, worse vision

## Summary

Retinal diseases encompass a broad spectrum of vision-threatening conditions. Diabetic retinopathy remains the leading cause of blindness in working-age adults, manageable with glycemic control, laser, and anti-VEGF therapy. Age-related macular degeneration is the leading cause in the elderly, with dry AMD managed by AREDS2 vitamins and emerging complement inhibitors for geographic atrophy, while wet AMD is highly treatable with anti-VEGF injections. Retinal vascular occlusions require prompt evaluation for embolic sources and treatment of macular edema. Retinal detachment is a surgical emergency, with high success rates if treated promptly. Advanced imaging, particularly OCT, has revolutionized diagnosis and monitoring. Understanding these conditions, their presentations, and evidence-based treatments is essential for preserving vision and improving outcomes for patients with retinal disease.
